---
title: "VAMHA–MYRHA Combination Improves Menstrual Regularity and Ovulation in PMOS: Randomized Multicentr"
id: "medrxiv-2-evaluation-of-the-efficacy-and-safety-of-combination-therapy-of-vamha-and-myrha"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-evaluation-of-the-efficacy-and-safety-of-combination-therapy-of-vamha-and-myrha"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# VAMHA–MYRHA Combination Improves Menstrual Regularity and Ovulation in PMOS: Randomized Multicentr
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-evaluation-of-the-efficacy-and-safety-of-combination-therapy-of-vamha-and-myrha
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This open-label, randomized, multicentre prospective study compared a combination of **VAMHA and MYRHA** tablets against standard non-hormonal therapy (Metformin 500 mg + Myoinositol 600 mg) in women with polyendocrine metabolic ovarian syndrome (**PMOS**, formerly PCOS). - Seventy-one women were randomized: Group A (VAMHA + MYRHA; n=37) and Group B (Metformin + Myoinositol; n=34). Treatment duration was 180 days with twice-daily dosing in both arms. - Primary outcome assessed restoration of regular menstruation. Significantly more participants in Group A achieved regular cycles (31) than in Group B (22) (p<0.05). - Ovulation rates favored the VAMHA–MYRHA group: 16 participants ovulated in Group A versus 6 in Group B (p<0.05). - Both groups showed significant improvements in menstrual irregularity and related symptoms; both arms also had significant reductions in **Anti-Mullerian Hormone (AMH)**, fasting insulin, and **body mass index (BMI)** (p<0.05). - Resolution of polycystic ovarian morphology on ultrasound occurred in 13 participants (38.23%) in Group A and 10 participants (33.33%) in Group B. - Safety: both therapies were reported as well tolerated with no major safety concerns documented in the manuscript. - Study registration: CTRI/2022/12/048147. Ethics approvals were obtained at the participating centres; informed consent was confirmed. - As a medRxiv preprint, the report has not been peer reviewed; the authors note data are contained in the manuscript and the findings should not yet guide clinical practice.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=9Lnzn8U8_9N4HDrsotVJs5160wIzGF.8G97V3Ui5IBs-1788392128.3860416-1.2.1.1-.22syiOzvEwEXS1OEXtF9qEmH8PExTaCS8Bcqbdqz8MWjDKxzbqvTYSHRc_bi3WV) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Evaluation of the Efficacy and Safety of Combination Therapy of Vamha and Myrha in the Management of PMOS: An Open-Label, Randomized, Multicentre, Comparative, Prospective Clinical Study Aarati Patil, Rahul Barathe, Deepali Murlidhar Tate, Keerti Kate, Shishir Pande, Nitin Gawande, Amruta More, Swapnali Mahadik, Kshitija Berde, Ritika Singhvi doi: https://doi.org/10.64898/2026.08.20.26360875 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Aarati Patil 1 Gynoveda Femtech Pvt. Ltd Access work Level-9, Eureka Tower, A-Wing Mindspace-IT Park, Chincholi Bunder Malad West, Mumbai, Maharashtra 400064.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Aarati%2BPatil%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Patil%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAarati%2BPatil%2B) Rahul Barathe 2 Dr. D. Y. Patil College of Ayurved and Research Centre, Pimpri-Chinchwad, Pune, Maharashtra, India.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rahul%2BBarathe%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Barathe%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARahul%2BBarathe%2B) Deepali Murlidhar Tate 3 Prabhankur Wellness Clinic, Hadapsar, Pune, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Deepali%2BMurlidhar%2BTate%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tate%20DM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADeepali%2BMurlidhar%2BTate%2B) Keerti Kate 4 Ayurveda Seva Sangh Ayurved Mahavidyalaya, Panchvati, Nashik, Maharashtra, India.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Keerti%2BKate%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kate%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKeerti%2BKate%2B) * For correspondence: kate.kirti@gmail.com Shishir Pande 5 Ayurveda Seva Sangh Ayurved Mahavidyalaya, Panchvati, Nashik, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shishir%2BPande%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pande%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShishir%2BPande%2B) Nitin Gawande 2 Dr. D. Y. Patil College of Ayurved and Research Centre, Pimpri-Chinchwad, Pune, Maharashtra, India.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nitin%2BGawande%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gawande%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANitin%2BGawande%2B) Amruta More 3 Prabhankur Wellness Clinic, Hadapsar, Pune, Maharashtra, India; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amruta%2BMore%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=More%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmruta%2BMore%2B) Swapnali Mahadik 6 Target Institute of Medical Education & Research Pvt. Ltd. 402, A/B/C, Jaswanti Allied Business Center, Ramchandra lane Extension, Kachpada, Malad (West), Mumbai-400064.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Swapnali%2BMahadik%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mahadik%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASwapnali%2BMahadik%2B) Kshitija Berde 7 Gynoveda Femtech Pvt. Ltd Access work Level-9, Eureka Tower, A-Wing Mindspace-IT Park, Chincholi Bunder Malad West, Mumbai, Maharashtra 400064; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kshitija%2BBerde%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Berde%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKshitija%2BBerde%2B) Ritika Singhvi 8 Target Institute of Medical Education & Research Pvt. Ltd. 402, A/B/C, Jaswanti Allied Business Center, Ramchandra lane Extension, Kachpada, Malad (West), Mumbai-400064 * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ritika%2BSinghvi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Singhvi%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARitika%2BSinghvi%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1290618/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1290618/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1290618/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1290618/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1290618/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Introduction: Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a common endocrine disorder affecting women of reproductive age. Besides reproductive and metabolic disturbances, PMOS negatively impacts psychological well-being and quality of life. Despite available treatment options, there remains a need for safe and effective therapies that improve both clinical symptoms and fertility outcomes. Aim: To compare the efficacy of VAMHA and MYRHA tablet combination therapy with standard non-hormonal therapy in restoring regular menstruation. Secondary objectives included assessment of ovulation, menstrual symptoms, polycystic ovarian morphology, hormonal and metabolic parameters, anthropometric measures, and skin manifestations. Study Design: Open-label, randomized, multicentre, prospective comparative clinical study. Methods: Seventy-one women with PMOS were randomized to Group A (n=37) or Group B (n=34). Group A received VAMHA and MYRHA tablets (2 tablets each), while Group B received Metformin 500 mg plus Myoinositol 600 mg (1 tablet), twice daily for 180 days. Data were recorded in Case Report Forms. Statistical Analysis: Continuous variables were summarized using mean and standard deviation, while categorical variables were expressed as frequencies and percentages. Appropriate statistical tests, including Chi-square, were used. A p-value ≤0.05 was considered significant. Results: Significantly more participants in Group A achieved regular menstrual cycles than Group B (31 vs. 22; p The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.01.20.26344416v2 "Assessing diagnostic accuracy of onchocerciasis rapid diagnostic tests using Bayesian latent class models") Posted September 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/02/2026.08.20.26360875.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.20.26360875v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/02/2026.08.20.26360875.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Evaluation of the Efficacy and Safety of Combination Therapy of Vamha and Myrha in the Management of PMOS: An Open-Label, Randomized, Multicentre, Comparative, Prospective Clinical Study Aarati Patil, Rahul Barathe, Deepali Murlidhar Tate, Keerti Kate, Shishir Pande, Nitin Gawande, Amruta More, Swapnali Mahadik, Kshitija Berde, Ritika Singhvi medRxiv 2026.08.20.26360875; doi: https://doi.org/10.64898/2026.08.20.26360875 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.20.26360875v1%26text%3DEvaluation%2520of%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Combination%2520Therapy%2520of%2520Vamha%2520and%2520Myrha%2520in%2520the%2520Management%2520of%2520PMOS%253A%2520An%2520Open-Label%252C%2520Randomized%252C%2520Multicentre%252C%2520Comparative%252C%2520Prospective%2520Clinical%2520Study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.20.26360875v1%26t%3DEvaluation%2520of%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Combination%2520Therapy%2520of%2520Vamha%2520and%2520Myrha%2520in%2520the%2520Management%2520of%2520PMOS%253A%2520An%2520Open-Label%252C%2520Randomized%252C%2520Multicentre%252C%2520Comparative%252C%2520Prospective%2520Clinical%2520Study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.20.26360875v1%26title%3DEvaluation%2520of%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Combination%2520Therapy%2520of%2520Vamha%2520and%2520Myrha%2520in%2520the%2520Management%2520of%2520PMOS%253A%2520An%2520Open-Label%252C%2520Randomized%252C%2520Multicentre%252C%2520Comparative%252C%2520Prospective%2520Clinical%2520Study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.20.26360875v1%26title%3DEvaluation%2520of%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Combination%2520Therapy%2520of%2520Vamha%2520and%2520Myrha%2520in%2520the%2520Management%2520of%2520PMOS%253A%2520An%2520Open-Label%252C%2520Randomized%252C%2520Multicentre%252C%2520Comparative%252C%2520Prospective%2520Clinical%2520Study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.20.26360875) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.20.26360875v1&count=horizontal&via=&text=Evaluation%20of%20the%20Efficacy%20and%20Safety%20of%20Combination%20Therapy%20of%20Vamha%20and%20Myrha%20in%20the%20Management%20of%20PMOS%3A%20An%20Open-Label%2C%20Randomized%2C%20Multicentre%2C%20Comparative%2C%20Prospective%20Clinical%20Study&counturl=www.medrxiv.org/content/10.64898/2026.08.20.26360875v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (614) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (896) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (327) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4771) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (407) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1615) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15837) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1195) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6983) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1057) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4987) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1426) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1738) * [Hematology](https:/
## Related Clinical Research

- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [Feasibility of Managing Community-Detected Type 2 Diabetes with WHO‑PEN in Rural Ethiopia](https://medichelpline.com/clinical-feed/medrxiv-7-feasibility-of-managing-diabetes-patients-identified-through-community.md)
- [Long-term Metformin Randomization Linked to Lower Dementia Risk and Better Memory in Diabetes Prev](https://medichelpline.com/clinical-feed/medrxiv-15-randomized-metformin-and-cognitive-outcomes-in-the-diabetes-prevention-program.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.